416 related articles for article (PubMed ID: 31099781)
21. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
23. CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites.
Jayavaradhan R; Pillis DM; Goodman M; Zhang F; Zhang Y; Andreassen PR; Malik P
Nat Commun; 2019 Jun; 10(1):2866. PubMed ID: 31253785
[TBL] [Abstract][Full Text] [Related]
24. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.
Kitamura K; Que L; Shimadu M; Koura M; Ishihara Y; Wakae K; Nakamura T; Watashi K; Wakita T; Muramatsu M
PLoS Pathog; 2018 Jun; 14(6):e1007124. PubMed ID: 29928064
[TBL] [Abstract][Full Text] [Related]
25. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
Ramanan V; Shlomai A; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
Sci Rep; 2015 Jun; 5():10833. PubMed ID: 26035283
[TBL] [Abstract][Full Text] [Related]
27. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
[TBL] [Abstract][Full Text] [Related]
28. Endogenous sequence patterns predispose the repair modes of CRISPR/Cas9-induced DNA double-stranded breaks in Arabidopsis thaliana.
Vu GTH; Cao HX; Fauser F; Reiss B; Puchta H; Schubert I
Plant J; 2017 Oct; 92(1):57-67. PubMed ID: 28696528
[TBL] [Abstract][Full Text] [Related]
29. Quantitative assessment of HR and NHEJ activities via CRISPR/Cas9-induced oligodeoxynucleotide-mediated DSB repair.
Du J; Yin N; Xie T; Zheng Y; Xia N; Shang J; Chen F; Zhang H; Yu J; Liu F
DNA Repair (Amst); 2018 Oct; 70():67-71. PubMed ID: 30212742
[TBL] [Abstract][Full Text] [Related]
30. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.
Tang L; Sheraz M; McGrane M; Chang J; Guo JT
PLoS Pathog; 2019 Apr; 15(4):e1007742. PubMed ID: 31026293
[TBL] [Abstract][Full Text] [Related]
31. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.
Zheng Q; Bai L; Zheng S; Liu M; Zhang J; Wang T; Xu Z; Chen Y; Li J; Duan Z
Mol Med Rep; 2017 Nov; 16(5):7199-7204. PubMed ID: 28944845
[TBL] [Abstract][Full Text] [Related]
32. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.
Karimova M; Beschorner N; Dammermann W; Chemnitz J; Indenbirken D; Bockmann JH; Grundhoff A; Lüth S; Buchholz F; Schulze zur Wiesch J; Hauber J
Sci Rep; 2015 Sep; 5():13734. PubMed ID: 26334116
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the Termini of Cytoplasmic Hepatitis B Virus Deproteinated Relaxed Circular DNA.
Cai D; Yan R; Xu JZ; Zhang H; Shen S; Mitra B; Marchetti A; Kim ES; Guo H
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055252
[TBL] [Abstract][Full Text] [Related]
34. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models.
Yi J; Lei X; Guo F; Chen Q; Chen X; Zhao K; Zhu C; Cheng X; Lin J; Yin H; Xia Y
Antiviral Res; 2023 Jul; 215():105618. PubMed ID: 37142191
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection.
Zhang X; Tian Y; Xu L; Fan Z; Cao Y; Ma Y; Li H; Ren F
Hepatol Int; 2022 Apr; 16(2):306-315. PubMed ID: 35298777
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
Liu X; Hao R; Chen S; Guo D; Chen Y
J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
[TBL] [Abstract][Full Text] [Related]
39. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus.
Sakuma T; Masaki K; Abe-Chayama H; Mochida K; Yamamoto T; Chayama K
Genes Cells; 2016 Nov; 21(11):1253-1262. PubMed ID: 27659023
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology.
Noor S; Rasul A; Iqbal MS; Ahmed B; Akash MSH; Qadir MI
Crit Rev Eukaryot Gene Expr; 2020; 30(3):273-278. PubMed ID: 32749114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
